Top 10 Psychedelic Papers of 2025

The review and meta-analysis (s=87; 2025) found esketamine's efficacy as an adjunctive therapy for treatment-resistant depression (TRD) to be modest (effect size 0. 23) and comparable to atypical antipsychotics. The review raises concerns about esketamine's abuse potential and unknown long-term effects. It also highlights regulatory issues, including deaths and emerging suicidality during clinical trials. That makes it useful as a map of the most notable psychedelic research published in 2025: it shows where evidence clusters, where the field is thin, and which claims need more cautious reading.

The mouse study examines how psilocybin affects different types of brain cells in the medial frontal cortex. The research found that psilocybin increases dendritic spine density in both pyramidal tract (PT) and intratelencephalic (IT) neurons, but only PT neurons are essential for psilocybin's anti-stress effects through 5-HT2A receptor activation. Its main value is mechanistic: it helps connect subjective or clinical effects to biology instead of treating the drug experience as a black box. Together with the other papers from the year, it shows which parts of psychedelic science were becoming more rigorous, more contested, or more clinically relevant.

The double-blind randomised clinical trial found that a single dose of psilocybin with brief psychotherapy did not reduce alcohol relapse rates or consumption compared to placebo in patients with alcohol use disorder (AUD) at 4-week or 6-month follow-up, though psilocybin participants reported additional reductions in craving and temptation to drink, suggesting larger trials are needed to evaluate this approach for severely affected patients. For readers, the value is not just the result but the study design: it shows how the most notable psychedelic research published in 2025 performs when tested under more structured clinical conditions.

The receptor profiling study maps the pharmacological activity of classical psychedelics across 318 human G-protein-coupled receptors and, for LSD, over 450 human kinases. It found that psychedelics act potently at nearly all serotonin, dopamine, and adrenergic receptors, with multiple 5-HT2A receptor signalling pathways linked to psychedelic effects in vivo. Its main value is mechanistic: it helps connect subjective or clinical effects to biology instead of treating the drug experience as a black box. Together with the other papers from the year, it shows which parts of psychedelic science were becoming more rigorous, more contested, or more clinically relevant.

This re-analysis of the COMPASS Phase IIb trial examines the relationships between psilocybin dose, psychedelic experiences, and therapeutic outcomes in treatment-resistant depression. Higher doses produced stronger psychedelic effects, and reductions in depression at Week 3 correlated most strongly with dimensions of Oceanic Boundlessness (r = −0. 508), Visual Restructuralization (r = −0. 516), and Emotional Breakthrough Inventory. It adds a concrete angle on the most notable psychedelic research published in 2025, helping readers understand the topic through evidence rather than broad claims alone.

This trial tests the most notable psychedelic research published in 2025 under more rigorous clinical conditions, moving the question beyond early pilot evidence. It helps readers see whether the approach can hold up when protocols are more standardised, outcomes are clearer, and follow-up becomes harder to ignore. For readers, the value is not just the result but the study design: it shows how the most notable psychedelic research published in 2025 performs when tested under more structured clinical conditions. Together with the other papers from the year, it shows which parts of psychedelic science were becoming more rigorous, more contested, or more clinically relevant.

The paper presents seven cryo-electron microscopy (cryo-EM) structures showing how different classes of psychedelic and non-psychedelic compounds interact with the serotonin (5-HT) 2A receptor-the primary target for classical psychedelics' therapeutic effects-revealing both shared and distinct binding patterns that could guide the development of new therapeutic compounds with improved side effect profiles. Its main value is mechanistic: it helps connect subjective or clinical effects to biology instead of treating the drug experience as a black box. Together with the other papers from the year, it shows which parts of psychedelic science were becoming more rigorous, more contested, or more clinically relevant.

The open-label trial conducted at Sheppard Pratt Hospital found that psilocybin decreases depressive symptoms in patients with severe treatment-resistant depression (TRD) at 3 weeks. For readers, the value is not just the result but the study design: it shows how the most notable psychedelic research published in 2025 performs when tested under more structured clinical conditions. Together with the other papers from the year, it shows which parts of psychedelic science were becoming more rigorous, more contested, or more clinically relevant.

The open-label trial shows promising results for the use of 5-MeO-DMT in the treatment of addiction, specifically alcoholism (AUD). Though uncontrolled, it provided a positive result for continuing this line of research. For readers, the value is not just the result but the study design: it shows how the most notable psychedelic research published in 2025 performs when tested under more structured clinical conditions. Together with the other papers from the year, it shows which parts of psychedelic science were becoming more rigorous, more contested, or more clinically relevant.

The open-label fixed-order dose-escalation trial evaluated inhaled DMT for treatment-resistant depression (TRD) for the first time. Results showed rapid and sustained antidepressant effects with a 21-point reduction on the Montgomery-Asberg Depression Rating Scale by day 7 (. 001), an 86% response rate, and a 57% remission rate lasting up to 3 months. For readers, the value is not just the result but the study design: it shows how the most notable psychedelic research published in 2025 performs when tested under more structured clinical conditions. Together with the other papers from the year, it shows which parts of psychedelic science were becoming more rigorous, more contested, or more clinically relevant.